Overview

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2026-05-04
Target enrollment:
Participant gender:
Summary
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborator:
National Institute for Health Research, United Kingdom
Treatments:
Olaparib
Pembrolizumab